Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation

被引:76
作者
Adkins, Farrell C. [1 ]
Gonzalez-Angulo, Ana Maria [2 ]
Lei, Xiudong [3 ]
Hernandez-Aya, Leonel F. [2 ]
Mittendorf, Elizabeth A. [1 ]
Litton, Jennifer K. [2 ]
Wagner, Jamie [1 ]
Hunt, Kelly K. [1 ]
Woodward, Wendy A. [4 ]
Meric-Bernstam, Funda [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
关键词
COMPARING TOTAL MASTECTOMY; 20-YEAR FOLLOW-UP; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; PREMENOPAUSAL WOMEN; CONSERVING SURGERY; RADIOTHERAPY; PHENOTYPE; PATTERNS; THERAPY;
D O I
10.1245/s10434-011-1920-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Triple-negative breast cancer (TNBC) is an aggressive subtype shown to have a high risk of locoregional recurrence (LRR). The purpose of this study was to determine the impact of operation type on LRR in TNBC patients. Methods. A total of 1325 patients with TNBC who underwent breast-conserving therapy (BCT) or mastectomy from 1980 to the present were identified. Clinical and pathological factors were compared by the chi-square test. LRR-free survival (LRRFS), distant metastasis-free survival, and overall survival were estimated by the Kaplan-Meier method. Multivariate analysis was performed by the Cox proportional hazard models. Results. BCT was performed in 651 patients (49%) and mastectomy in 674 (51%). The mastectomy group had larger tumors, a higher incidence of lymphovascular invasion, and higher pathologic N stage (all P < 0.001). At 62-month median follow-up, LRR was seen in 170 (26%) in the BCT group and 203 (30%) in the mastectomy group. Five-year LRRFS rates were higher in the BCT group (76% vs. 71%, P = 0.032), as was distant metastasis-free survival (68% vs. 54%, P < 0.0001) and overall survival (74% vs. 63%, P < 0.0001). On multivariate analysis, T stage (hazard ratio [HR] 1.37, P = 0.006), high nuclear grade (HR 1.92, P = 0.002), lymphovascular invasion (HR 1.93, P < 0.0001), close/positive margins (HR 1.89, P < 0.0001), and use of non-anthracycline or taxane-based adjuvant chemotherapy (HR 2.01, P < 0.0001) increased the LRR risk, while age [ 50 years was protective (HR 0.73, P = 0.007). Operation type (mastectomy vs. BCT, HR 1.07, P = 0.55) was not statistically significant. Conclusions. BCT is not associated with increased LRR rates compared to mastectomy. TNBC should not be considered a contraindication for breast conservation.
引用
收藏
页码:3164 / 3173
页数:10
相关论文
共 50 条
  • [21] Advances in the Treatment of Triple-negative Early Breast Cancer
    Basso, Stefano M. M.
    Santeufemia, Davide A.
    Fadda, Giovanni M.
    Tozzoli, Renato
    D'Aurizio, Federica
    Lumachi, Franco
    MEDICINAL CHEMISTRY, 2016, 12 (03) : 268 - 272
  • [22] Triple-Negative Breast Cancer: Clinical and Histological Correlations
    Elsawaf, Zeinab
    Sinn, Hans-Peter
    BREAST CARE, 2011, 6 (04) : 273 - 278
  • [23] Advances in the systemic treatment of triple-negative breast cancer
    Lebert, J. M.
    Lester, R.
    Powell, E.
    Seal, M.
    McCarthy, J.
    CURRENT ONCOLOGY, 2018, 25 : S142 - S150
  • [24] The epidemiology of triple-negative breast cancer, including race
    Trivers, Katrina F.
    Lund, Mary Jo
    Porter, Peggy L.
    Liff, Jonathan M.
    Flagg, Elaine W.
    Coates, Ralph J.
    Eley, J. William
    CANCER CAUSES & CONTROL, 2009, 20 (07) : 1071 - 1082
  • [25] Mammographic and clinicopathological features of triple-negative breast cancer
    Gao, B.
    Zhang, H.
    Zhang, S-D
    Cheng, X-Y
    Zheng, S-M
    Sun, Y-H
    Zhang, D-W
    Jiang, Y.
    Tian, J-W
    BRITISH JOURNAL OF RADIOLOGY, 2014, 87 (1039)
  • [26] Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk
    Phipps, Amanda I.
    Buist, Diana S. M.
    Malone, Kathleen E.
    Barlow, William E.
    Porter, Peggy L.
    Kerlikowske, Karla
    Li, Christopher I.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (03) : 671 - 678
  • [27] The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data
    Rajesh Raju
    Aswathy Mary Paul
    Vivekanand Asokachandran
    Bijesh George
    Lekshmi Radhamony
    Meena Vinaykumar
    Reshmi Girijadevi
    Madhavan Radhakrishna Pillai
    Breast Cancer Research, 16
  • [28] The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data
    Raju, Rajesh
    Paul, Aswathy Mary
    Asokachandran, Vivekanand
    George, Bijesh
    Radhamony, Lekshmi
    Vinaykumar, Meena
    Girijadevi, Reshmi
    Pillai, Madhavan Radhakrishna
    BREAST CANCER RESEARCH, 2014, 16 (06)
  • [29] Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey
    Verma, S.
    Provencher, L.
    Dent, R.
    CURRENT ONCOLOGY, 2011, 18 (04) : 180 - 190
  • [30] Stratifying triple-negative breast cancer: which definition(s) to use?
    Adamo, Barbara
    Anders, Carey K.
    BREAST CANCER RESEARCH, 2011, 13 (02):